Shorter SBRT Treatment Is Safe, Efficacious in High-Risk Prostate CancerJanuary 28th 2021
A shorter course of stereotactic body radiotherapy (SBRT) has been shown to have encouraging efficacy with favorable toxicity when used in patients with high-risk prostate cancer in a multi-institutional, international setting, according to findings from a study published in the International Journal of Radiation Oncology, Biology, Physics.
Padeliporfin ImPACT Granted Fast Track Status for Upper-Tract Urothelial CancerJanuary 19th 2021
The FDA has granted a fast track designation to padeliporfin Immune Photo Activated Cancer Therapy (ImPACT) for use in the treatment of patients with low-grade and unifocal upper-tract urothelial cancer (UTUC), according to an announcement from Steba Biotech.
FDA Updates Darolutamide Label for Prostate CancerJanuary 11th 2021
The FDA has approved a supplemental new drug application to add overall survival (OS) and other secondary end point data from the phase 3 ARAMIS trial (NCT02200614) to the prescribing information for darolutamide (Nubeqa) for the treatment of patients with nonmetastatic prostate cancer (nmCRPC).
FDA Approves PSMA-Targeted Imaging Drug for Prostate CancerDecember 1st 2020
The FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11), a drug for PET imaging of prostate-specific membrane antigen (PSMA) positive levels in men with suspected prostate cancer metastasis, who may be curable by surgery or radiation therapy.
FDA Approves Companion Diagnostic, FoundationOne Liquid CDx, for Olaparib in Prostate CancerNovember 9th 2020
The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic with olaparib (Lynparza), which is indicated for select patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer (mCRPC).
Nivolumab Plus Cabozantinib Gets Priority Review for Advanced RCC TreatmentOctober 20th 2020
The FDA has granted a priority review designation to a supplemental biologics license application and supplemental new drug application for nivolumab (Opdivo) plus cabozantinib (Cabometyx) for the treatment of patients with advanced renal cell carcinoma.
FDA Approval Sought for TLX591-CDx for Prostate Cancer ImagingSeptember 28th 2020
A new drug application has been submitted to the FDA for TLX591-CDx, a radiopharmaceutical product that targets prostate-specific membrane antigen, for the imaging of prostate cancer through the use of positron emission tomography.
Molecularly-Guided Therapy Improves Outcomes in Kidney CancerSeptember 22nd 2020
Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma (ccRCC).
EPI-7386 Gets Fast Track Designation for mCRPC TreatmentSeptember 15th 2020
The FDA granted a fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who are resistant to standard-of-care options, according to an announcement from ESSA Pharma Inc.
Stay Vigilant When Treating Cancer During the COVID-19 PandemicSeptember 7th 2020
The novel coronavirus disease (COVID-19) continues to impact the care of patients with metastatic renal cell carcinoma (mRCC) and other cancers in a multitude of ways, according to Toni K. Choueiri, MD, but those working in the field of oncology are rising up to the challenge by learning as much as possible about the virus to make the best treatment decisions possible for their patients.
Better Access to Germline Testing Is Needed in the Prostate Cancer SpaceAugust 28th 2020
Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.
Immunotherapy Is Promising for Cisplatin-Ineligible Metastatic Urothelial CancerAugust 18th 2020
Several trials in the field of first-line metastatic urothelial cancer are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab (Bavencio). However, no phase 3 trials have shown that first-line pembrolizumab (Keytruda) is better than gemcitabine and platinum-based therapy followed by avelumab as maintenance, according to Guru P. Sonpavde, MD.
Examining Racial Genomics in Prostate CancerAugust 8th 2020
Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.
Infigratinib Is Active in Metastatic Urothelial CancerJune 2nd 2020
Infigratinib was found to demonstrate clinical activity in patients with metastatic urothelial carcinoma, regardless of what line of therapy it was administered, according to results of a retrospective analysis presented at the 2020 ASCO Virtual Scientific Program.
Relugolix May Become New Standard of Care for Advanced Prostate CancerJune 1st 2020
Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks, fast T-recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer.
Age and Gender Can Affect RCC OutcomesMay 24th 2020
Understanding the implications of age and gender upon safety and efficacy outcomes in patients with renal cell carcinoma (RCC) who are receiving targeted treatment options is critical to the delivery of individualized care, according to Rana R. McKay, MD.